In the pursuit to cure* chronic hepatitis C virus (HCV) genotype 1 infection…Consider OLYSIO® for your patients with 24 weeks’ treatment duration
100% (10/10) of patients with cirrhosis achieved cure* in the 24-week group
IFN- and RBV-free treatment option = OLYSIO® + sofosbuvir (SOF)
- 24 weeks of treatment duration for patients with cirrhosis
Use with RBV
- Results from treatment arms containing RBV in addition to OLYSIO® and sofosbuvir in the COSMOS trial are not shown because efficacy was similar with or without RBV, and thus addition of RBV to OLYSIO® and sofosbuvir is not recommended.
IFN=interferon; P/R=peginterferon/ribavirin; RBV=ribavirin.
*Virologic cure (SVR12) was defined as sustained virologic response 12 weeks after the planned end of treatment (EOT).
†Null responders to prior P/R therapy.
‡Viral relapse rates are calculated with a denominator of subjects with HCV RNA not detected at EOT and with at least 1 follow‐up HCV RNA assessment.
COSMOS (IFN-free) study design and baseline demographics
IFN- and RBV-free treatment option = OLYSIO® + SOF
COSMOS: open‑label, randomized Phase 2 trial to investigate the efficacy and safety of 12 or 24 weeks of OLYSIO® in combination with SOF without or with RBV in HCV genotype 1‑infected prior null responders with METAVIR fibrosis score F0‑F2, or treatment‑naïve subjects and prior null responders (to P/R therapy) with METAVIR fibrosis score F3‑F4 and compensated liver disease.
- OLYSIO® 150 mg once daily + SOF 400 mg once daily
- Primary endpoint: SVR12: sustained virologic response 12 weeks after planned end of treatment [EOT]
IFN=interferon; P/R=peginterferon/ribavirin; RBV=ribavirin; SOF=sofosbuvir.
*This case is representative of a patient in the COSMOS clinical trial. The image is not of an actual patient studied in COSMOS.
Baseline demographic and disease characteristics in OLYSIO® + SOF without RBV arms